Literature DB >> 18034596

Delayed-release Multi Matrix System (MMX) mesalazine in ulcerative colitis: a viewpoint by Ake Nilsson.

Ake Nilsson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18034596     DOI： 10.2165/00003495-200767170-00011

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  3 in total

1.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.

Authors:  Michael A Kamm; William J Sandborn; Miguel Gassull; Stefan Schreiber; Lechoslaw Jackowski; Todd Butler; Andrew Lyne; David Stephenson; Mary Palmen; Raymond E Joseph
Journal:  Gastroenterology       Date:  2006-10-12       Impact factor: 22.682

2.  A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.

Authors:  Cosimo Prantera; Angelo Viscido; Livia Biancone; Antonio Francavilla; Lucio Giglio; Massimo Campieri
Journal:  Inflamm Bowel Dis       Date:  2005-05       Impact factor: 5.325

3.  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.

Authors:  Gary R Lichtenstein; Michael A Kamm; Prabhakar Boddu; Natalya Gubergrits; Andrew Lyne; Todd Butler; Kirstin Lees; Raymond E Joseph; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-01       Impact factor: 11.382
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.